In contrast to previous clinical trials using MSC-based therapy for RA, no statistically significant differences in serum levels of CRP, anti-CCP, IL-17, and IFN-γ cytokine levels were observed [43,87]. The gene discussed is CRP; the disease is rheumatoid arthritis.